California Low-Cost Insulin Faces Delays After Price-Cap Veto

California’s effort to produce low-cost insulin is facing unanticipated delays and likely won’t meet the anticipated 2024 timeline, the state health agency informed Bloomberg Law.

The state initially aimed to deliver biosimilar insulin under its own CalRx label sometime next year. But that timeline has extended beyond then, California Health and Human Services Secretary Dr. Mark Ghaly said in a statement responding to an inquiry.

Gov. Gavin Newsom (D) announced in March that the state had contracted with the nonprofit drugmaker Civica to produce biosimilar insulin that would be available at a cost as low as $30 for a 10mL ...